TNFSF13B and systemic lupus erythematosus: Belimumab, an anti-BAFF antibody, is a representative of B-cell-targeted therapy approved for treating SLE.32 Belimumab, targets only B cells, therefore, we hypothesized that 2D4 would be more effective in treating SLE than Belimumab.